Legend Biotech (LEGN) Non-Current Receivables: 2020-2025
Historic Non-Current Receivables for Legend Biotech (LEGN) over the last 4 years, with Sep 2025 value amounting to $193.0 million.
- Legend Biotech's Non-Current Receivables rose 99.30% to $193.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.0 million, marking a year-over-year increase of 99.30%. This contributed to the annual value of $112.7 million for FY2024, which is 108.32% up from last year.
- Per Legend Biotech's latest filing, its Non-Current Receivables stood at $193.0 million for Q3 2025, which was down 0.64% from $194.2 million recorded in Q2 2025.
- Over the past 5 years, Legend Biotech's Non-Current Receivables peaked at $194.2 million during Q2 2025, and registered a low of -$22,000 during Q1 2021.
- Its 3-year average for Non-Current Receivables is $120.4 million, with a median of $104.7 million in 2024.
- Per our database at Business Quant, Legend Biotech's Non-Current Receivables plummeted by 144.44% in 2021 and then spiked by 131.71% in 2025.
- Legend Biotech's Non-Current Receivables (Quarterly) stood at -$22,000 in 2021, then reached $54.1 million in 2023, then soared by 108.32% to $112.7 million in 2024, then soared by 99.30% to $193.0 million in 2025.
- Its Non-Current Receivables stands at $193.0 million for Q3 2025, versus $194.2 million for Q2 2025 and $159.7 million for Q1 2025.